A CASE FOR CHANGE IN PATIENT CARE
THE MULTIPLE MYELOMA
CALL‑TO‑ACTION
DOWNLOAD THE CALL-TO-ACTIONA Johnson & Johnson Initiative,
Developed with a Global Expert Collaboration Council
This Call-to-Action outlines high-priority unmet needs and recommended areas of focus for the global multiple myeloma community, as identified by the Collaboration Council.
DOWNLOAD THE CALL-TO-ACTIONThe multiple myeloma difference
Incurable
Despite significant scientific advancements, multiple myeloma remains an incurable disease.1
Complex
The highly heterogeneous nature of multiple myeloma has required a myriad of treatment options, which all need careful selection and often combination or sequencing, specific to each patient.1 This creates complexity for healthcare teams and their patients.2
Continuous
Multiple myeloma is characterized by cycles of response, remission, and relapse.1 It can require continuous treatment, which places a significant physical,3,4 psychological,5 and financial6 burden on everyone involved.
The Global MM Collaboration Council
MEET OUR GLOBAL EXPERTSAbbreviations & References
MM, multiple myeloma.
- Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011;8(8):479-91.
- Hernández-Rivas J, Ríos-Tamayo R, Encinas C, Alonso R, Lahuerta JJ. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res. 2022;10(1):1.
- Zaleta AK, Miller MF, Olson JS, Yuen EYN, LeBlanc TW, Cole CE, et al. Symptom burden, perceived control, and quality of life among patients living with multiple myeloma. J Natl Compr Canc Netw. 2020;18(8):1087-95.
- Quinn B, Ludwig H, Bailey A, Khela K, Marongiu A, Carlson KB, et al. Physical, emotional and social pain communication by patients diagnosed and living with multiple myeloma. Pain Manag. 2022;12(1):59-74.
- Gatopoulou X, Iraqi W, Morgan K, Helme K, Spain VA, Redfearn J, et al. The burden of a multiple myeloma diagnosis on patients and caregivers in the first year: Western European findings. Clinicoecon Outcomes Res. 2022;14:731-53.
- Tran D, Kamalakar R, Manthena S, Karve S. Economic burden of multiple myeloma: results from a large employer-sponsored real-world administrative claims database, 2012 to 2018. Blood. 2019;134(Supplement_1):3414.
This Call-to-Action outlines high-priority unmet needs and recommended areas of focus for the global multiple myeloma community, as identified by the Collaboration Council.
THE CALL-TO-ACTION